Source comparison
MK-677 Oral GH Secretagogue Complete Guide 2026 vs Injectable GH Peptides
Administration Oral, once daily Subcutaneous injection, 2–3× daily Subcutaneous injection, daily MK-677's oral bioavailability eliminates injection site reactions and simplifies compliance in extended protocols Mechanism Ghrelin receptor agonist → endogenous G
This comparison does not assign a generated winner or score.
- Administration
- Oral, once daily
- Subcutaneous injection, 2–3× daily
- Subcutaneous injection, daily
- MK-677's oral bioavailability eliminates injection site reactions and simplifies compliance in extended protocols
- Mechanism
- Ghrelin receptor agonist → endogenous GH pulses
- GHSR agonist → GH pulses
- Direct GH replacement
- MK-677 preserves natural pulsatile GH secretion; exogenous GH suppresses it entirely
- IGF-1 Elevation
- 60–90% above baseline (sustained)
- 40–70% above baseline (transient, 3–4 hour peaks)
- 150–300% above baseline (dose-dependent)
- MK-677 produces moderate, sustained IGF-1 elevation without the pharmacokinetic peaks/troughs of injectable peptides
- Appetite Effect
- Strong increase (ghrelin-mediated)
- Moderate increase
- Neutral to slight decrease
- Appetite stimulation is unavoidable with MK-677. Plan protocols around this or exclude subjects unable to manage caloric intake
- Cost (research-grade)
- ~$60–80/month at 25mg daily
- ~$120–180/month (dosing 2–3× daily)
- ~$400–800/month
- MK-677 offers the most cost-effective sustained GH secretagogue option for budget-constrained labs
- HPTA Suppression
- None (does not suppress endogenous production)
- None
- Complete suppression during use
- MK-677 and GHRPs do not require post-cycle recovery protocols. Exogenous GH does